← BackBioventus Inc. · Surgical & Medical Instruments & ApparatusBVS
Low riskNext report: In 6 days (est.)
The short versionA profitable company with steady sales. Institutions are adding.
Going well
- Profitable
- Brings in more cash than it spends
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 18% to their holdings in the quarter ending June 2026 (100 bought, 60 sold)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$14.73-1.5% that day
- Company value
- $1.0B
- Share price times all shares
- Price vs profit (P/E)
- 19.1x
- You pay about $19 for each $1 of yearly profit
- Price vs sales
- 1.8x
- Company value is 1.8 times a year of sales
- Cash vs value
- 3%
- Cash as a share of company value
- Debt vs value
- 28%
- Debt as a share of company value
From BVS's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$153.2M+3.8% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $581.8M, up 3.1% from the 12 months before. Over 5 years, sales grew about 12% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- MissReturn on equity 15%+Earns a lot on the money owners have in the business.13.7%
- MissDebt under half of equityNot relying on borrowed money.1.60x equity
- MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.4.0%
- MissProfitable every yearSteady profits, not one good year.4 of 7 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$72.1M
- MissShare count not growingNot diluting owners. Falling means buybacks.+12.3% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.68.3%
- Revenue
- $568.1M
- -0.9% vs prior year
- 5-year growth
- +12.1%/yr
- revenue, per year
- Total debt
- $294.0M
- 1.60x equity
- Current ratio
- 1.70x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 27, 2026- Revenue
- $153.2M
- +3.8% YoY
- EPS
- $0.47
- vs $0.11
- Op. margin
- 12.5%
- +0.1 pts
- Gross margin
- 69.0%
- -0.1 pts
- Free cash flow
- $18.9M
- Share count
- +3.4%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 1
- Normal week
- 0.2
- vs normal
- 2.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
▲Accumulating+17.5%Institutions added 17.5% to their holdings. 100 bought, 60 sold. 7 quarters of net buying in a row.
Shares held by institutions59.8M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
+4.2%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
1.1x · $248.5M debtShares outstandingLatest reported
71MNext reportIn 6 days (est.)Estimated from the same quarter last year
- Results filedAug 5
- Results filedMay 6
- Results filedMar 5
- Results filedNov 4, 2025
- Results filedAug 6, 2025
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
Latest filings
Straight from SEC EDGAR
Option exercisePat BeyerDirector
32,282 shares
- +42% of holdings
- Now owns 108,718 shares
- Filed 2 days after trade
- Also: Stock award
Option exercisePhilip G. CowdyDirector
32,282 shares
- +276% of holdings
- Now owns 43,982 shares
- Filed 2 days after trade
- Also: Stock award
Option exerciseWilliam A HawkinsDirector
39,789 shares
- +15% of holdings
- Now owns 297,640 shares
- Filed 2 days after trade
- Also: Stock award
Option exerciseMary Kay LadoneDirector
32,282 shares
- +41% of holdings
- Now owns 111,263 shares
- Filed 2 days after trade
- Also: Stock award
Option exerciseMichelle Mcmurry-heathDirector
32,282 shares
- +72% of holdings
- Now owns 77,279 shares
- Filed 2 days after trade
- Also: Stock award
Option exerciseGuido J NeelsDirector
32,282 shares
- +38% of holdings
- Now owns 117,523 shares
- Filed 2 days after trade
- Also: Stock award